he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-05-02走近右心室高压 温暖“蓝唇人”
- 2022-04-25中国艾滋病疫苗或六月开启III期临床试验,有望突破HIV困局
- 2022-04-252013年国际抗癫痫联合会抗癫痫制剂使用指南
- 2022-04-20吡仑帕奈辅助用药可改善部分发作型病症患者的症状
- 罕见病例:自发性颞极性扩张伴癫痫发作
- FDA批准Aptiom用于治疗患者癫痫发作
- 心理百科:春节期间小心疾病
- 预测癫痫患者再入院风险
- 癫痫治疗障碍仍难以克服
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 儿童癫痫的发病因素是什么?
- 三庚酸酯可治疗1型转运体缺陷综合征
- 2015第31届国际癫痫大会(IEC)
- 黑芝麻的营养价值 吃黑芝麻的好处
- 2013国际抗癫痫联合会抗癫痫药用指南
- 癫痫定位新方法:无框架立体定向脑电图技术
- 癫痫患者手术评估新型工具
- 2015 神经系统疾病诊疗进展
- 癫痫患者如何克服忘记吃药的问题?
- 综述:癫痫持续状态诊治最新进展
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 特发性癫痫大发作药物治疗的首选
- 抗癫痫药物预防新发癫痫:任重而道远
- 北京癫痫医院治疗费用
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- FDA警告怀孕期间使用丙戊酸钠药物
- 治愈成人癫痫病大概需要多少费用
- 2015 大脑疾病诊疗进展大盘点
- 最佳癫痫病治疗方式症状是什么
- 怎样服用抗癫痫药物可以降低副产物
- 癫痫疾病的体检诊断方法有哪些 癫痫疾病的体检费用高吗
- 【用药问答】癫痫大发作和局限性发作的首选用药为?
- 癫痫治疗 中医疗法治疗癫痫可不愁
- Diabetologia:激活但功能受损的记忆Tregs在1型糖尿病患者进展缓慢的过程中逐渐扩展到
- 北京癫痫病手术额度
- Circ Ep:左室纤细的高血压患者新发房颤增加SCD风险
- 怎样放射治疗癫痫病放射治疗方法
- 好的择业观才能帮助癫痫病人更好融入价值观
- 癫痫病诊断的依据是什么
- 后期癫痫的表现是什么 讲述癫痫疾病的症状
- 水肿癫痫能治愈吗 治疗癫痫有这几个步骤